Biotest AG: EUR 64.4 million operating profit in core business of Biotest
News: Biotest AG / Key word(s): Preliminary Results / EUR 64.4 million operating profit in core business of Biotest The therapy business and the toll manufacturing outside the US as well as the plasma collection in the US and in Europe are the core business of Biotest and are reported as Continued Operations. These recorded an increase in profitability and revenues compared to the previous year. According to preliminary and unaudited figures, the Biotest Group reports EBIT (Earnings before interest and tax) in Continued Operations in the amount of EUR 64.4 million in the full year 2016. This represents an increase of 72.7% compared with the previous year (FY 2015: EUR 37.3 million). Compared to the previous year revenues in Continued Operations increased by 3.5% to EUR 553.1 million in 2016 (2015: EUR 534.6 million). The business activities, which - in line with the strategic realignment and the contract to sell this business signed in January - will not be continued in future, are reported as Discontinued Operation. In this segment revenues of EUR 57.3 million were recorded in 2016 (2015: EUR 55.0 million). Earnings before interest and tax (EBIT) of the Discontinued Operations in the amount of EUR -84.4 million resulted mainly from extraordinary one time effects and reduce the operating profit of the group in 2016 (pls. ref. to Ad-hoc of 23rd Jan, 2017). In 2015 the Biotest Group has reported earnings before interest and tax (EBIT) of all business areas of EUR -71.8 million. Despite the positive development of the business activities in 2016 in the Continued Operations (EUR 64.4 million) EBIT of all business areas amounted to EUR -20.0 million. Revenues of all business areas of the Biotest Group reached EUR 610.4 million in the full year 2016 after EUR 589.6 million in 2015 (+3.5%). The EBIT-margin in the Continued Operations increased from 7.0% in 2015 to 11.6% in 2016. Biotest will publish final results for the Financial Year 2016 and the annual report on March 30th, 2017. About Biotest AG IR contact Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 Disclaimer 16.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 - 8 01-0 |
Fax: | 0 61 03 - 8 01-150 |
E-mail: | investor_relations@biotest.de |
Internet: | http://www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |